

Lioe-Fee de Geus-Oei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8051043/publications.pdf>

Version: 2024-02-01

193
papers

7,546
citations

81900

39
h-index

62596

80
g-index

199
all docs

199
docs citations

199
times ranked

11855
citing authors

#	ARTICLE	IF	CITATIONS
1	High Performance of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer. <i>Respiration</i> , 2014, 87, 32-37.	2.6	2,816
2	Monitoring and Predicting Response to Therapy with ¹⁸ F-FDG PET in Colorectal Cancer: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2009, 50, 43S-54S.	5.0	197
3	A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 694-703.	6.4	182
4	Biological correlates of FDG uptake in non-small cell lung cancer. <i>Lung Cancer</i> , 2007, 55, 79-87.	2.0	174
5	Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer. <i>Cancer</i> , 2007, 110, 1654-1664.	4.1	141
6	The role of ¹⁸ fluorodeoxyglucose positron emission tomography in initial staging and restaging after chemotherapy for testicular germ cell tumours. <i>BJU International</i> , 2002, 89, 549-556.	2.5	135
7	Chemotherapy Response Evaluation with ¹⁸ F-FDG PET in Patients with Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1592-1598.	5.0	109
8	Methodological considerations in quantification of oncological FDG PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1408-1425.	6.4	108
9	Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of ¹⁸ F-FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1485-1493.	1.1	107
10	¹⁸ F-FDG PET Early Response Evaluation of Locally Advanced Non-Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1528-1534.	5.0	104
11	Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: Spatial distribution and prognostic value of GLUT1 and MCT4. <i>Lung Cancer</i> , 2012, 76, 316-323.	2.0	99
12	Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. <i>Annals of Oncology</i> , 2008, 19, 348-352.	1.2	98
13	Scintigraphic Techniques for Early Detection of Cancer Treatment-Induced Cardiotoxicity. <i>Journal of Nuclear Medicine</i> , 2011, 52, 560-571.	5.0	92
14	A comparison of the diagnostic value of MRI and ¹⁸ F-FDG-PET/CT in suspected spondylodiscitis. <i>Infection</i> , 2017, 45, 41-49.	4.7	90
15	The role of [¹⁸ F]fluorodeoxyglucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy. <i>Cancer</i> , 2011, 117, 4582-4594.	4.1	79
16	PET in the management of locally advanced and metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 395-407.	27.6	75
17	¹⁸ F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. <i>Journal of Nuclear Medicine</i> , 2006, 47, 770-5.	5.0	71
18	¹⁸ F-FDG PET/CT Optimizes Treatment in <i>Staphylococcus Aureus</i> Bacteremia and Is Associated with Reduced Mortality. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1504-1510.	5.0	70

#	ARTICLE	IF	CITATIONS
19	Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. <i>Journal of Nuclear Medicine</i> , 2006, 47, 945-9.	5.0	70
20	A Curve-Fitting Approach to Estimate the Arterial Plasma Input Function for the Assessment of Glucose Metabolic Rate and Response to Treatment. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1933-1939.	5.0	68
21	The Impact of Optimal Respiratory Gating and Image Noise on Evaluation of Intratumor Heterogeneity on ¹⁸ F-FDG PET Imaging of Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1692-1698.	5.0	67
22	The diagnostic value of 18F-FDG-PET/CT and MRI in suspected vertebral osteomyelitis – a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 798-805.	6.4	67
23	EUS-FNA for the detection of left adrenal metastasis in patients with lung cancer. <i>Lung Cancer</i> , 2011, 73, 310-315.	2.0	61
24	Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 194-207.	4.4	61
25	18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study. <i>PLoS ONE</i> , 2018, 13, e0192859.	2.5	57
26	Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 117, 49-54.	0.6	55
27	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. <i>European Radiology</i> , 2021, 31, 6001-6012.	4.5	53
28	Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. <i>Surgery</i> , 2005, 137, 246-249.	1.9	52
29	Predictive and prognostic value of FDG-PET. <i>Cancer Imaging</i> , 2008, 8, 70-80.	2.8	52
30	Comparison of Tumor Volumes Derived from Glucose Metabolic Rate Maps and SUV Maps in Dynamic ¹⁸ F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 892-898.	5.0	51
31	Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. <i>European Radiology</i> , 2014, 24, 3242-3250.	4.5	51
32	Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 768-774.	6.4	49
33	FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. <i>Annals of Oncology</i> , 2006, 17, 1650-1655.	1.2	48
34	Cost-Effectiveness of FDG-PET/CT for Cytologically Indeterminate Thyroid Nodules: A Decision Analytic Approach. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3263-3274.	3.6	47
35	New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. <i>Biomarkers</i> , 2015, 20, 143-148.	1.9	47
36	The role of 18F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2037-2047.	6.4	45

#	ARTICLE	IF	CITATIONS
37	Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. <i>Endocrine Reviews</i> , 2018, 39, 154-191.	20.1	45
38	Timeliness of lung cancer diagnosis and treatment in a rapid outpatient diagnostic program with combined 18FDG-PET and contrast enhanced CT scanning. <i>Lung Cancer</i> , 2012, 75, 336-341.	2.0	42
39	FDG-PET in colorectal cancer. <i>Cancer Imaging</i> , 2006, 6, S71-S81.	2.8	41
40	18F-fluorodeoxyglucose positron-emission tomography combined with computed tomography as a diagnostic tool in native valve endocarditis. <i>Nuclear Medicine Communications</i> , 2018, 39, 747-752.	1.1	37
41	Quantitative Assessment of Heterogeneity in Tumor Metabolism Using FDG-PET. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e725-e731.	0.8	35
42	Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients. <i>Radiation Oncology</i> , 2012, 7, 150.	2.7	33
43	Diagnostic value of FDG-PET/(CT) in children with fever of unknown origin and unexplained fever during immune suppression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1916-1923.	6.4	33
44	Multimodality Imaging to Predict Response to Systemic Treatment in Patients with Advanced Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0120823.	2.5	33
45	Lymphoscintigraphy and sentinel lymph node biopsy in vulvar carcinoma: update from a European expert panel. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1261-1274.	6.4	32
46	Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric ¹⁸ F-FDG PET Images in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1033-1039.	5.0	31
47	Comparison of toxicity and outcome in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy using IMRT or VMAT. <i>Radiotherapy and Oncology</i> , 2017, 122, 295-299.	0.6	31
48	Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPA-Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1777-1784.	5.0	29
49	Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). <i>Journal of Nuclear Cardiology</i> , 2016, 23, 824-832.	2.1	29
50	Metal Artifact Reduction of CT Scans to Improve PET/CT. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1867-1872.	5.0	29
51	Modalities for image- and molecular-guided cancer surgery. <i>British Journal of Surgery</i> , 2018, 105, e69-e83.	0.3	29
52	Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. <i>Targeted Oncology</i> , 2014, 9, 339-347.	3.6	28
53	Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems™ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 841-852.	2.0	28
54	The Value of ¹⁸ F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever. <i>Journal of Nuclear Medicine</i> , 2018, 59, 127-133.	5.0	26

#	ARTICLE	IF	CITATIONS
55	Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer â€” a randomized controlled trial. <i>Gynecologic Oncology</i> , 2020, 159, 672-680.	1.4	26
56	Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 957-967.	2.3	25
57	Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer. <i>Medical Physics</i> , 2018, 45, 2143-2153.	3.0	25
58	Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer. <i>Pharmaceutics</i> , 2020, 12, 193.	4.5	25
59	Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1858-1867.	6.4	24
60	Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. <i>Contrast Media and Molecular Imaging</i> , 2014, 9, 237-245.	0.8	24
61	Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. <i>Journal of Nuclear Medicine</i> , 2018, 59, 194-196.	5.0	24
62	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1386-1406.	6.4	24
63	Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males. <i>Metabolism: Clinical and Experimental</i> , 2020, 106, 154167.	3.4	23
64	Brain Inflammation and Intracellular α -Synuclein Aggregates in Macaques after SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 776.	3.3	23
65	Clinical applications of positron emission tomography in sarcoma management. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 195-204.	2.4	22
66	Radiomics in Vulvar Cancer: First Clinical Experience Using ¹⁸ F-FDG PET/CT Images. <i>Journal of Nuclear Medicine</i> , 2019, 60, 199-206.	5.0	22
67	Cardiac molecular pathways influenced by doxorubicin treatment in mice. <i>Scientific Reports</i> , 2019, 9, 2514.	3.3	22
68	[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1970-1984.	6.4	22
69	Metabolic Subtyping of Pheochromocytoma and Paraganglioma by ¹⁸ F-FDG Pharmacokinetics Using Dynamic PET/CT Scanning. <i>Journal of Nuclear Medicine</i> , 2019, 60, 745-751.	5.0	21
70	Gadopentetate Dimeglumine and FDG Uptake in Liver Metastases of Colorectal Carcinoma as Determined with MR Imaging and PET. <i>Radiology</i> , 2005, 237, 181-188.	7.3	20
71	Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 314-321.	2.6	20
72	Improving the Spatial Alignment in PET/CT Using Amplitude-Based Respiration-Gated PET and Respiration-Triggered CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1817-1822.	5.0	20

#	ARTICLE	IF	CITATIONS
73	The impact of respiratory gated positron emission tomography on clinical staging and management of patients with lung cancer. <i>Lung Cancer</i> , 2015, 90, 217-223.	2.0	19
74	Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial. <i>Diabetologia</i> , 2018, 61, 2386-2397.	6.3	19
75	Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 1130-1141.	1.5	19
76	Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2174-2188.	6.4	19
77	FDG-PET/CT based response-adapted treatment. <i>Cancer Imaging</i> , 2012, 12, 324-335.	2.8	17
78	Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, 473-479.	0.6	17
79	First Clinical Experience Using Stereotactic Breast Biopsy Guided by 99mTc-Sestamibi. <i>American Journal of Roentgenology</i> , 2017, 209, 1367-1373.	2.2	17
80	Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1527-1537.	6.4	17
81	Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. <i>Nuclear Medicine Communications</i> , 2009, 30, 550-557.	1.1	16
82	Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET. <i>Clinical Colorectal Cancer</i> , 2011, 10, E1-E5.	2.3	16
83	Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic ¹⁸ F Fluorodeoxyglucose PET. <i>Radiology</i> , 2017, 283, 547-559.	7.3	16
84	Inclusion of Incidental Radiation Dose to the Cardiac Atria and Ventricles Does Not Improve the Prediction of Radiation Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 434-441.	0.8	16
85	Striatal dopamine synthesis capacity in autism spectrum disorder and its relation with social defeat: an [18F]-FDOPA PET/CT study. <i>Translational Psychiatry</i> , 2021, 11, 47.	4.8	16
86	Postural Headache in Marfan Syndrome Associated with Spinal Cysts and Liquor Hypotension. <i>Neuropediatrics</i> , 2009, 40, 201-204.	0.6	15
87	Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings. <i>Clinical Breast Cancer</i> , 2018, 18, 9-18.	2.4	15
88	Can transplant renal scintigraphy predict the duration of delayed graft function? A dual center retrospective study. <i>PLoS ONE</i> , 2018, 13, e0193791.	2.5	15
89	Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery. <i>International Journal of Molecular Sciences</i> , 2017, 18, 307.	4.1	14
90	Quantitative Volumetric Assessment of Ablative Margins in Hepatocellular Carcinoma: Predicting Local Tumor Progression Using Nonrigid Registration Software. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	1.3	14

#	ARTICLE	IF	CITATIONS
91	Maximizing the potency of oxaliplatin coated nanoparticles with folic acid for modulating tumor progression in colorectal cancer. <i>Materials Science and Engineering C</i> , 2021, 120, 111678.	7.3	14
92	Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2980-e2994.	3.6	14
93	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. <i>Frontiers in Oncology</i> , 2021, 11, 772530.	2.8	14
94	Immunotherapy response evaluation with 18F-FDG-PET in patients with advanced stage renal cell carcinoma. <i>World Journal of Urology</i> , 2013, 31, 841-846.	2.2	13
95	Comparison of a Free-Breathing CT and an Expiratory Breath-Hold CT with Regard to Spatial Alignment of Amplitude-Based Respiratory-Gated PET and CT Images. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 269-273.	0.8	13
96	The Predictive Value of Early In-Treatment ¹⁸ F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1243-1248.	5.0	13
97	Can [18F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer?. <i>Abdominal Radiology</i> , 2020, 45, 301-306.	2.1	13
98	Nanocarriers as a Tool for the Treatment of Colorectal Cancer. <i>Pharmaceutics</i> , 2021, 13, 1321.	4.5	13
99	Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. <i>Cancers</i> , 2020, 12, 3870.	3.7	13
100	Early myocardial deformation abnormalities in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 127-135.	2.5	12
101	Adding the temporal domain to PET radiomic features. <i>PLoS ONE</i> , 2020, 15, e0239438.	2.5	12
102	Performance of 3DOSEM and MAP algorithms for reconstructing low count SPECT acquisitions. <i>Zeitschrift Fur Medizinische Physik</i> , 2016, 26, 311-322.	1.5	10
103	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. <i>Targeted Oncology</i> , 2018, 13, 641-648.	3.6	10
104	Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4804.	4.1	10
105	SNMMI Procedure Standard/EANM Practice Guideline for Molecular Breast Imaging with Dedicated ¹⁸ F-Cameras. <i>Journal of Nuclear Medicine Technology</i> , 2022, 50, 103-110.	0.8	10
106	Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold. <i>European Journal of Cancer</i> , 2016, 56, 54-58.	2.8	9
107	Cell-Based Tracers as Trojan Horses for Image-Guided Surgery. <i>International Journal of Molecular Sciences</i> , 2021, 22, 755.	4.1	9
108	Nuclear medicine radiomics in precision medicine: why we can't do without artificial intelligence. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 278-290.	0.7	9

#	ARTICLE	IF	CITATIONS
109	Nuclear medicine imaging methods of radiation-induced cardiotoxicity. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 597-610.	4.6	9
110	FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3452-3469.	6.4	9
111	Nodular Fasciitis on F-18 FDG PET. <i>Clinical Nuclear Medicine</i> , 2010, 35, 830-831.	1.3	8
112	Long-term prognostic value of single-photon emission computed tomography myocardial perfusion imaging after primary PCI for STEMI. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 1287-1293.	1.2	8
113	Fluorescence and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma. <i>International Journal of Cancer</i> , 2018, 142, 2118-2129.	5.1	8
114	External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 249-256.	0.6	8
115	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. <i>Anticancer Research</i> , 2019, 39, 1309-1316.	1.1	8
116	18F-PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 458-473.	4.6	8
117	Evaluating the use of optimally respiratory gated 18F-FDG-PET in target volume delineation and its influence on radiation doses to the organs at risk in non-small-cell lung cancer patients. <i>Nuclear Medicine Communications</i> , 2016, 37, 66-73.	1.1	8
118	Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. <i>Cancers</i> , 2021, 13, 6088.	3.7	8
119	Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 6164.	3.7	8
120	Effects of hyperoxygenation on FDG-uptake in head-and-neck cancer. <i>Radiotherapy and Oncology</i> , 2006, 80, 51-56.	0.6	7
121	Shortened dynamic FDG-PET protocol to determine the glucose metabolic rate in non-small cell lung carcinoma. , 2008, , .		7
122	Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. <i>Investigational New Drugs</i> , 2013, 31, 881-890.	2.6	7
123	Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for attenuation correction in 18F-FDG PET/CT. <i>Nuclear Medicine Communications</i> , 2014, 35, 472-477.	1.1	7
124	Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma. <i>EJNMMI Research</i> , 2019, 9, 24.	2.5	7
125	Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma. <i>Diagnostic and Interventional Radiology</i> , 2019, 25, 451-458.	1.5	7
126	Personalising sarcoma care using quantitative multimodality imaging for response assessment. <i>Clinical Radiology</i> , 2021, 76, 313.e1-313.e13.	1.1	7

#	ARTICLE	IF	CITATIONS
127	Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1266-1272.	6.4	6
128	18F-FDG PET/CT in Detecting Metastatic Infection in Children. <i>Clinical Nuclear Medicine</i> , 2016, 41, 278-281.	1.3	6
129	Lifestyle-Intervention-Induced Reduction of Abdominal Fat Is Reflected by a Decreased Circulating Glycerol Level and an Increased HDL Diameter. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1900818.	3.3	6
130	The Influence of the Exclusion of Central Necrosis on [18F]FDG PET Radiomic Analysis. <i>Diagnostics</i> , 2021, 11, 1296.	2.6	6
131	Image-guided adaptive radiotherapy in patients with locally advanced non-small cell lung cancer: the art of PET. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 369-384.	0.7	6
132	Cerebral [18F]-FDOPA Uptake in Autism Spectrum Disorder and Its Association with Autistic Traits. <i>Diagnostics</i> , 2021, 11, 2404.	2.6	6
133	PET-guided treatment algorithms in oesophageal cancer: the promise of the near future!. <i>Journal of Thoracic Disease</i> , 2017, 9, 2736-2739.	1.4	5
134	The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 513-522.	2.5	5
135	Limited clinical value of two consecutive post-transplant renal scintigraphy procedures. <i>European Radiology</i> , 2020, 30, 452-460.	4.5	5
136	Cholesterol-functionalized carvedilol-loaded PLGA nanoparticles: anti-inflammatory, antioxidant, and antitumor effects. <i>Journal of Nanoparticle Research</i> , 2020, 22, 1.	1.9	5
137	Fludeoxyglucose positron emission tomography-computed tomography scan showing polyarthritis in a patient with an atypical presentation of Henoch-Schönlein vasculitis without clinical signs of arthritis: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 159.	0.8	4
138	Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring 18F-FDG-PET/CT. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 7, 16-22.	2.9	4
139	Abstract OT3-2-01: IMPACT: IMaging PATients for Cancer drug selectIon "Metastatic breast cancer (MBC)., 2015, , .		4
140	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 250-264.	0.7	4
141	Evaluation of FDG-PET/CT Use in Children with Suspected Infection or Inflammation. <i>Diagnostics</i> , 2020, 10, 715.	2.6	4
142	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 37-39.	0.6	4
143	The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review. <i>Diagnostics</i> , 2022, 12, 715.	2.6	4
144	Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients" A Dose-Finding Study (HORA EST HCC Trial). <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1057-1063.	2.0	4

#	ARTICLE	IF	CITATIONS
145	Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules. <i>Endocrine Connections</i> , 2022, 11, .	1.9	4
146	False Positive 18F-FDG PET/CT Due to Inflamed Concha Bullosa. <i>Clinical Nuclear Medicine</i> , 2012, 37, 509-510.	1.3	3
147	Letter to the Editor: Interobserver Variability of Heart-to-Mediastinum Ratio in I-123 MIBG Sympathetic Imaging. <i>Current Cardiology Reports</i> , 2012, 14, 389-390.	2.9	3
148	PET imaging during hypoglycaemia to study adipose tissue metabolism. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13120.	3.4	3
149	Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic heart failure without considerable ischaemia. <i>Netherlands Heart Journal</i> , 2019, 27, 81-92.	0.8	3
150	Novel frontiers of dedicated molecular imaging in breast cancer diagnosis. <i>Translational Cancer Research</i> , 2018, 7, S295-S306.	1.0	3
151	Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma. <i>Diagnostics</i> , 2021, 11, 2271.	2.6	3
152	Tracers to Monitor the Response to Chemotherapy: In Vitro Screening of Four Radiopharmaceuticals. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 457-465.	1.0	2
153	Hybrid 18F-FDG PET/CT of colonic anastomosis. <i>Nuklearmedizin - NuclearMedicine</i> , 2012, 51, 252-256.	0.7	2
154	Nodular Fasciitis on 18F-FDG PET. <i>Clinical Nuclear Medicine</i> , 2013, 38, 442-443.	1.3	2
155	Avastin Scintigraphy in Surveillance of Bevacizumab Treatment in a Patient With Neurofibromatosis Type 2. <i>Clinical Nuclear Medicine</i> , 2014, 39, 277-280.	1.3	2
156	Improving the Spatial Alignment in PET/CT Using Amplitude-Based Respiration-Gated PET and Patient-Specific Breathing-Instructioned CT. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 154-159.	0.8	2
157	Experimental validation of absolute SPECT/CT quantification for response monitoring in patients with coronary artery disease. <i>EJNMMI Physics</i> , 2021, 8, 48.	2.7	2
158	Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11555-11555.	1.6	2
159	Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer. <i>PLoS ONE</i> , 2022, 17, e0261939.	2.5	2
160	Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. <i>Anticancer Research</i> , 2015, 35, 5601-6.	1.1	2
161	Design and evaluation of a modular multimodality imaging phantom to simulate heterogeneous uptake and enhancement patterns for radiomic quantification in hybrid imaging: A feasibility study. <i>Medical Physics</i> , 2022, 49, 3093-3106.	3.0	2
162	Intraoperative Near-Infrared Fluorescence Imaging with Indocyanine Green for Identification of Gastrointestinal Stromal Tumors (GISTs), a Feasibility Study. <i>Cancers</i> , 2022, 14, 1572.	3.7	2

#	ARTICLE	IF	CITATIONS
163	A new colleague in nuclear medicine, the clinical technologist: quo vadis?. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	6.4	2
164	F-18 FDG PET/CT as a Crucial Guide Toward Optimal Treatment Planning in a Case of Postirradiation Sarcoma 10 Years After Primary Bone Lymphoma of the Pelvis. Clinical Nuclear Medicine, 2011, 36, 565-567.	1.3	1
165	Poster walks. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 229-259.	6.4	1
166	Shortened Dynamic ¹⁸ F-FDG PET. Journal of Nuclear Medicine, 2011, 52, 1330.1-1330.	5.0	1
167	Catecholamines influence myocardial ¹²³ I MIBG uptake in neuroblastoma patients. Nuklearmedizin - NuclearMedicine, 2013, 52, 228-234.	0.7	1
168	From Incidentaloma to Oncocytoma: A Role for Hybrid Molecular Imaging in Characterising Renal Masses?. European Urology, 2016, 69, 417-418.	1.9	1
169	Diagnostic delay in primary osteosarcoma (OST) and Ewing sarcoma (ES) of bone in relation to metabolic activity on FDG PET/CT. European Journal of Cancer, 2017, 72, S153.	2.8	1
170	Considerations on bone volume normalization in quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1351-1352.	6.4	1
171	Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?. Diagnostics, 2021, 11, 553.	2.6	1
172	Nuclear Medicine Imaging of Fever of Unknown Origin. , 2020, , 199-211.		1
173	Early response evaluation using ¹⁸ F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent. Nuklearmedizin - NuclearMedicine, 2021, 60, 411-416.	0.7	1
174	2101 Evaluation of neoadjuvant chemotherapy with FDG PET/CT and MRI in adult patients with Ewing's sarcoma (ES) and osteosarcoma (OS): beyond RECIST. European Journal of Cancer, Supplement, 2009, 7, 168.	2.2	0
175	Malignant Transformation in an Area With Elevated F-18 FDG Uptake Within a Low Metabolic Benign Neurofibroma. Clinical Nuclear Medicine, 2010, 35, 271-272.	1.3	0
176	In-treatment assessment of response in locally advanced NSCLC: Paving the way for personalized medicine. Lung Cancer, 2014, 86, 374.	2.0	0
177	EP-1851: Quantitative assessment of glucose metabolic rate within NSCLC histologies using dynamic ¹⁸ F-FDG PET. Radiotherapy and Oncology, 2016, 119, S871.	0.6	0
178	PO-0919: Optimal respiratory gated FDG-PET for characterizing intra-tumour heterogeneity in lung cancer. Radiotherapy and Oncology, 2016, 119, S445.	0.6	0
179	PV-0372: Histology-specific quantitative mapping and targeting of glucose and glutamine metabolism in NSCLC. Radiotherapy and Oncology, 2017, 123, S200-S201.	0.6	0
180	The role of proportionate kinetic growth rate fraction in future remnant liver function over volume determined by ^{99m} Tc-Mebrofenin hepatobiliary scintigraphy including SPECT and computed tomography in the risk prediction of postoperative mortality in ALPPS. Surgery, 2019, 165, 1244-1245.	1.9	0

#	ARTICLE	IF	CITATIONS
181	Global cardiac sympathetic denervation is associated with diffuse myocardial fibrosis in non-ischemic cardiomyopathy. <i>Europace</i> , 2021, 23, .	1.7	0
182	Sympathetic innervation pattern in NICM patients with ventricular tachycardia -anteroseptal versus inferolateral substrates-. <i>Europace</i> , 2021, 23, .	1.7	0
183	18F-FDG-PET/CT imaging in fever and inflammation of unknown origin. , 2021, , .		0
184	Gastroesophageal Reflux and Myocardial Imaging. <i>Clinical Nuclear Medicine</i> , 2000, 25, 834.	1.3	0
185	Metastasized Medullary Thyroid Carcinoma: Detection and Therapy Using Radiolabeled Gastrin Analogs. , 2010, , 416-432.		0
186	Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1062-1062.	1.6	0
187	Nuclear medicine in precision oncology: a foreword. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 231-233.	0.7	0
188	2-[18F]FDG PET/CT in Fever of Unknown Origin. , 2022, , 209-216.		0
189	Diagnostics in Patients Suspect for Breast Cancer in The Netherlands. <i>Current Oncology</i> , 2021, 28, 4998-5008.	2.2	0
190	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
191	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
192	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
193	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0